WebMD Health Management Discusses Q3 2013 Results - Earnings Call Transcript

Oct.29.13 | About: WebMD Health (WBMD)

WebMD Health (NASDAQ:WBMD)

Q3 2013 Earnings Call

October 29, 2013 4:45 pm ET

Executives

Risa Fisher

Martin J. Wygod - Chairman, Member of Executive Committee and Member of Strategic Planning Committee

David J. Schlanger - Chief Executive Officer

Peter Anevski - Chief Financial Officer and Executive Vice President

Analysts

Alexander Y. Draper - Raymond James & Associates, Inc., Research Division

Steve Rubis - Stifel, Nicolaus & Co., Inc., Research Division

Operator

Good afternoon, and welcome to the WebMD Health Corp.'s Third Quarter 2013 Conference Call. Today's call is being recorded. I will now turn the call over to Risa Fisher, Vice President of Investor Relations.

Risa Fisher

Good afternoon. This conference call is to discuss WebMD's third quarter results. The earnings release issued today by WebMD is available at www.wbmd.com in the Investor Relations section. The release includes reconciliations between GAAP and non-GAAP financial measures, which will be discussed during this call.

The explanatory paragraphs in the release concerning forward-looking disclosures and related risks and uncertainties also apply to forward-looking disclosures made during this call, including those regarding our guidance on future financial results and other projections or measures of WebMD's future performance. Further information regarding WebMD, including information concerning risks and uncertainties, can be found in WebMD's SEC filings and the information on this conference call is intended to be presented in conjunction with such filings.

Joining us on today's call are Marty Wygod, Chairman of WebMD; David Schlanger, Chief Executive Officer; and Pete Anevski, Chief Financial Officer. At the conclusion of our prepared remarks, we will open the call and take questions.

I'd now like to turn the call over to Marty Wygod, Chairman of WebMD.

Martin J. Wygod

Good afternoon, and thank you for joining us this afternoon. During the quarter, our Board of Directors appointed David Schlanger, CEO. David has been serving as interim CEO since May. Additionally, Steve Zatz has been named President. Steve, who had been heading our Professional Network, is now responsible for both our consumer and our physician networks. We expect that Steve's appointment to this newly created position will create a leadership structure that allow us to capitalize on market opportunities where our consumers and physician audience and our resources can be leveraged to bring new product to market more effectively.

We also continue to build our depth of management talent. Recent additions to our team include a new Chief Communications Officer, a new Head of Marketing Sciences, new Sales and Marketing Leadership and most recently, Judy Smythe [ph], the new President and COO of our private portal.

During the quarter, we completed a tender offer to purchase 5 million shares of our common stock and since the end of the quarter, we purchased an additional 5.5 million shares that were held by Carl Icahn. In total, since January 2012, we have repurchased 17,900,000 -- 17,900,000 shares at the average price of $29.78. Without these repurchases, our shares outstanding would be 45% higher than they are today.

Additionally, we repurchased $148 million principal amounts of our convertible notes. We are pleased we have been able to complete these buybacks.

As you can see from our performance and our recent stock repurchases, we are confident about the opportunities ahead. The health care landscape is changing rapidly, and I believe there are significant new market opportunities that are merging with WebMD's assets, particularly our highly engaged physician and consumer audiences who advantage us, as we create new sets of services and revenue streams.

I would now like to turn the call over to David Schlanger.

David J. Schlanger

Thanks, Marty. We're pleased to report improved third quarter results and to increase our revenue and earnings expectations for the balance of 2013. The positive momentum in our public portal's advertising business that we have seen emerged in the last few quarters is attributable to a combination of both external and internal factors. Externally, while there are challenges that remain with respect to our biopharmaceutical customers, including some conservatism impacting approval cycles and duration of marketing commitments, we believe that the overall advertising and marketing environment has improved as patent expirations of blockbuster drugs and the associated ripple effects have largely filtered through the system.

In addition, in the next few years, we expect to see a significant number of new product approvals for therapies targeted to niche audiences. As a result of the changing environment, we are exiting 2013 without the significant pharma industry headwinds that we experienced in the prior year.

Internally, we have worked hard to become a more customer-centric organization. We have introduced more flexible program configurations and have become more transparent when it comes to performance, as well as pricing through the unbundling of our offerings. Our enhanced analytics and insights capabilities have enabled us to quantify and demonstrate the value of our marketing platform to existing and prospective customers across a broader range of our product portfolio. As a result of these and other efforts, we are continuing to see the return of customers that had either reduced their spend with WebMD or stopped working with us for a time in favor of the other digital marketing tactics.

From an audience perspective, WebMD's reach to consumers and physicians has continued to grow strongly. Beginning in July, we began experiencing strong growth across our network and as a result, the WebMD Health Network reached a record of 138 million average monthly unique users during the third quarter and delivered 2.95 billion page views, increases of 29% and 15%, respectively, over the prior year period. In each of the months of August and September, we delivered over 1 billion page views, a new record for our company.

To put the scale of our multi-screen platform into perspective, according to recent comScore rankings, even while other health information sites are seeing declines in their traffic, the WebMD Health Network ranked #1 in the health information category, #1 among mobile health destinations, #1 in each of the 50 largest condition-suffering populations online and #31 of the top 100 web properties across all categories.

Our traffic growth is being driven by a range of factors, most notably the rapid adoption of mobile devices as an Internet access point, which has contributed to the significant increases in the utilization of our mobile offerings. Despite this trend in mobile adoption, unique visitors to our PC-based offerings in the third quarter remained steady, growing 3% over the prior year period. This is a strong indicator that when engaging with health and wellness content and tools, users rely on the larger screen size of a PC for many of their activities.

During the third quarter, approximately 34% of our page view traffic was from a U.S. desktop, 31% was from a U.S. smartphone, 8% was from a U.S. tablet device and 26% was international. Our year-over-year decline in U.S. PC page views was 13%, a significant improvement compared to the declines of 19% and 21% that we experienced in the first and second quarters of 2013. And if you combine tablet and PC page views together, then the decline is reduced to 4% as compared to the 12% and 13% decline in the first and second quarters. It's important to note that we are able to monetize tablet traffic in a similar manner to the PC.

Through our Medscape properties, we are also the leading online destination for health care professionals. During the quarter across our multi-screen platform, we averaged approximately 5.5 million physician sessions per month, an increase of 10% over the prior year period. To put Medscape scale into perspective, on an annual basis, 625,000 registered U.S. physicians are active on Medscape, a substantial majority of the actively practicing physicians in the U.S.

WebMD has been able to achieve its industry-leading scale and engagement, thanks in large part to the trust both consumers and health care professionals have in our brands. One of the unique characteristics of the WebMD Health Network is that we own and program our sites with a commitment to editorial excellence and high-quality original health programming. As a result, we're able to both deliver an engaging experience for our end-users and also a marketing platform that is a great value to our advertisers and program sponsors.

Our newest content area, the Health Care Reform Center, was launched during the quarter. We offer interactive tools and content to help consumers understand and navigate the changes that are taking place in health insurance coverage beginning in 2014. This is an example of how our unique approach to simplifying complex information and empowering health care decision-making is being applied to help consumers better understand how to navigate the Affordable Care Act. We have been hosting a number of live events on our site and participation engagement and user feedback has been very positive.

As Marty alluded to earlier, one of our goals is to leverage our capabilities and expertise across our businesses. The new tools within our ACA center that allow consumers to compare plans, estimate premiums and subsidies and understand their insurance options were derived from capabilities that we have been offering within our private portal product portfolio and are an example of this renewed cost business focus. In addition, our focus on empowering, understanding of and decision-making under the Affordable Care Act has allowed us to create a user audience that opens up new commercial opportunities for us, with health plans and governmental entities who are looking to reach individuals who will be participating in this new health insurance marketplace.

Turning to mobile. You've heard us talk previously about making the WebMD user experience more personal in an effort to drive deeper user engagement and increased user frequency. The highly targeted mobile apps we previously introduced, including WebMD Baby, WebMD Pregnancy and the WebMD Pain Coach are great examples of what we've been able to do in personalizing our mobile experience for specialized audiences.

During the quarter, we launched a redesigned version of our flagship WebMD app, which leverages much of what we have learned from our specialized apps regarding personalization and user engagement, but for a much larger audience. The new WebMD app provides personalized engaging, multimedia lifestyle content, along with the physician review health content and interactive tools that have driven the WebMD app success to date. The new app allows the user to customize content based on his or her own healthy living interest and goals. It also includes expanded local search for health providers and enhanced health information that users can choose from and save on over 26,000 conditions, drugs and first aid topics. Since its launch, we've seen significant increases in key engagement measures including visits, page views and time spent.

Across our base of advertisers, including both consumer products and biopharma companies, we are seeing increased demand for new ad formats and technologies and for access to our mobile audiences. While we view mobile as an incremental opportunity, we are still in the very early days of mobile monetization.

During the third quarter, we launched our first customer for our newly redesigned Medscape mobile brand alerts, a multi-screen native ad solution for the physician marketplace. Customer feedback to date has been very positive and several additional programs are set to launch this quarter. Other mobile ad products and multi-screen native capabilities are being introduced across our consumer and physician networks.

Another area of strategic focus is to make better use of our unique audience insights to improve the experience for our users and customers. One example of this is the WebMD cold and flu symptoms across the nation map and companion health center, which we optimized for mobile and launched earlier this month for the second consecutive flu season to help consumers stay ahead of cold and flu symptoms. WebMD's cold and flu map uses a combination of geo-location data and information compiled from millions of Symptom Checker visits to present a realtime analysis of the geographic spread of cold and flu, providing consumers with the latest updates on the severity of cold and flu in their geography. We have found that our Symptom Checker data is not only highly correlated to the CDC data, but is also available weeks earlier than the CDC data which has a dual benefit. For consumers, it provides them information that helps them stay one step ahead of the flu. In the case of one of our large CPG customers, they can use that information to present targeted advertising to consumers at a time when they are considering their preparedness options.

As we talked about on our last call, one of our strategic priorities is to establish WebMD and Medscape as the hub of a set of services that will facilitate information exchange and digital communication and transaction between patients and their health care providers. The launch of our new WebMD and Medscape apps included a feature that is the first step in connecting patients to their health care providers. The new WebMD app will connect with and support the new patient instruction feature in our Medscape app for health care professionals.

Medscape patient instructions allows physicians to securely send information -- send education and instructions on thousands of conditions, procedures and drugs to their patients. Patients can securely and conveniently read the instructions and information on the WebMD app for iPhone, as well as WebMD's mobile web and desktop sites.

Last week, as a first step to accelerate our connectivity efforts, we acquired Avado, an innovative technology company. Avado has developed a cloud-based patient relationship management solution that will serve as a key building block for our patient engagement platform, supporting a full suite of services connecting patients to their physicians. As our health care system evolves and as consumers and health care professionals assume more financial risk for the provision of care, patient engagement and management tools will be essential to producing quality outcomes and reducing costs. As Marty referenced, this is an example of how internal alignment of our consumer and physician operations will better enable us to evolve into a unified channel of communication and data exchange and take advantage of new market opportunities to create incremental revenue streams.

Turning to our Private Portal business. We continue to be on track for a January 1 launch date for the Blue Cross/Blue Shield Federal Employee program, the largest single contract in the history of WebMD Health Services. I expect 2014 will be the first time in several years that we will see significant growth in the private portal.

In summary, we will exit the year operating in an improved external environment and have regained momentum in our current revenue streams. We are taking the steps needed to create additional advertising and sponsorship opportunities, including in mobile, and we are working on the longer-term strategy to be best positioned to leverage our brand, audiences, capabilities and market leadership into diversified revenue streams and additional long-term growth opportunities.

I'd now like to turn the call over to Peter at this time.

Peter Anevski

Thanks, David. Our third quarter results were consistent with our financial guidance. Third quarter revenue was $130.9 million compared to $117.5 million last year, an increase of 11%. Public portal advertising and sponsorship revenue was $109.6 million compared to $97.6 million in the prior year. Private Portal services revenue was $21.3 million compared to $19.9 million in the prior year.

Third quarter adjusted EBITDA increased 80% to $31.7 million, or 24% of revenue, compared to $17.6 million, or 15% of revenue, in the prior year period. The increased margin is attributable to higher revenues, as well as lower expenses resulting from savings achieved through our previously announced December 2012 workforce and other cost reductions.

During the quarter, we recorded an after-tax loss on convertible notes of $2 million related to the purchase of $100 million principal amount of our 2 1/4% convertible notes due 2016. Third quarter net income was $3.2 million or $0.06 per diluted share compared to a net loss of $885,000 or $0.02 per diluted share in the prior year period. Net income would have been $5.2 million or $0.10 per diluted share in the current period, excluding the after tax loss on convertible notes of $2 million or $0.04 per diluted share.

Net loss in the prior year period would have been $3.1 million or $0.06 per diluted share, excluding after-tax income from discontinued operations of $2.2 million or $0.04 per diluted share.

Operating cash flow was approximately $28 million for the third quarter. As we have stated in the past, quarterly operating cash flows can be impacted by the timing of competition accruals and other accruals in relation to quarter's end, the timing of interest payments on our convertible notes and the billing and collection of receivables from our customers.

Capital expenditures were $2.5 million in the quarter. During the quarter, WebMD utilized $170.5 million in cash to repurchase 5 million of shares of our common stock in a tender offer, $7.7 million of cash to repurchase 258,000 shares of our common stock under our authorized share buyback program and as previously mentioned, $101.8 million in cash to repurchase $100 million principal amount of our 2 1/4% convertible notes due 2016.

As of September 30, WebMD had approximately $776 million in cash and cash equivalents and $700 million in aggregate principal amount of convertible notes outstanding.

Subsequent to quarter end, WebMD utilized $177.3 million in cash to repurchase all of the 5.5 million shares of WebMD common stock beneficially owned by Carl Icahn and certain of his affiliates, and $48.6 million in cash to purchase $47.8 million principal amount of our 2 1/4% convertible notes due 2016.

As of today, WebMD has approximately 40.5 million shares of its common stock outstanding which includes approximately 1 million unvested shares of restricted stock, approximately $550 million in cash and cash equivalents and $652 million in aggregate principal amount of convertible notes outstanding. We have approximately $54 million remaining in our authorized share buyback program.

Turning to our guidance for the balance of this year, as David mentioned, the strength in our third quarter results and improvements in our Public Portal's business is reflected in the increased revenue and earnings guidance we issued today. For the fourth quarter, we expect revenue to be in excess of $141 million, adjusted EBITDA to be in excess of $36 million and net income to be in excess of $7.7 million.

For the full year, we expect revenue to be in excess of $510 million, adjusted EBITDA to be in excess of $118 million and net income to be in excess of $12 million. We expect 2013 revenue distribution to be approximately 84% from Public Portal's advertising and sponsorship, representing growth of 9% or greater over the prior year; approximately 16% from Private Portal services, representing growth of 4% or greater in the prior year. We expect the weighted average basic and diluted share count for the year to be approximately 47 million and 49 million, respectively. We expect capital expenditures for the year to be approximately $15 million to $20 million.

A schedule summarizing our financial guidance is included in today's press release. Our guidance does not include the impact, if any, of future deployment of capital for items, such as share repurchases or acquisitions, gains and losses from discontinued operations or other nonrecurring one-time or unusual items.

I'd now like to open the call up for your questions. Operator, at this time, we'll take questions.

Question-and-Answer Session

Operator

[Operator Instructions] Our first question comes from Sandy Draper.

Alexander Y. Draper - Raymond James & Associates, Inc., Research Division

I'll try to limit it to one and then maybe come back into the queue. I guess the first question or my question is around the mobile side. When I think about mobile, on one hand, you lose space, you don't have as much opportunity to advertise and build out the inventory. The flip side, which I think is a little bit unique to health care and WebMD, is you obviously got a very, very tailored audience, if someone's downloading a specific mobile app for a specific condition. So I'm just curious, I know it's early days for mobile, but in your conversations with customers, how are they sort of thinking about price versus value or the whole value chain of mobile versus the traditional desktop?

David J. Schlanger

I think, Sandy, across our platform whether it's mobile, or on a desktop, on a tablet, we have a very unique audience that's really not easily accessible elsewhere on the web. And what we're seeing from a customer perspective is, particularly as it relates to mobile and tablet, when they're interested in those unique audiences we have, they're interested in those audiences at pricing that's relatively consistent across the platform. So again, we think mobile's a substantial opportunity from a monetization perspective because we have that unique audience, we have it at scale and that's the audience that our advertisers are seeking out.

Alexander Y. Draper - Raymond James & Associates, Inc., Research Division

Okay, great. That's really helpful. Maybe if I could just sneak in one very quick financial one. If you could comment, it looks like the guidance for CapEx is coming down. Anything going on there, any deferrals, or just no real need to spend as much as you thought originally?

Peter Anevski

Some of that is just timing. In terms of the initiative that we have underway, the money that we thought we'd spend this year, will just end up getting spent in the first quarter of next year. So there's nothing in terms of significant deferral of any kind. It's just simply timing on the projects that we have underway.

Operator

Our next question comes from Steve Rubis from Stifel.

Steve Rubis - Stifel, Nicolaus & Co., Inc., Research Division

You obviously beat numbers pretty well, but my question is in terms of deferred revenue growth. It seems that your growth rate there has decelerated this quarter. And I'm wondering if it's related to patent cliffs hitting or what's going on and how do you view that deferred revenue going forward, especially in the fourth quarter?

Peter Anevski

It has nothing to do with patent cliffs. And as we've said in the past, deferred revenue is not something that we look at as an indicator of growth or an indicator of our potential. There's a lot of things that impact deferred revenue, contractual terms, timing of billing, et cetera. And so it's not something that I would look at as an indicator of anything, but it's definitely not related to this, to the patent expiration.

Steve Rubis - Stifel, Nicolaus & Co., Inc., Research Division

Got it. And then in terms of mobile, do you expect to really kind of accelerate monetization in 2014? Or is that a 2015 type of event? Can you give us any sort of timing around that?

David J. Schlanger

No. We expect mobile to be an opportunity for us in 2014. We've recently launched a whole new set of mobile ad products across our portfolio on both the consumer and the professional side. And as we said in the prepared remarks, on the professional side, we've been experiencing sales traction this year. We launched our first new native mobile customer this quarter, several more are planned -- we have planned launches for several more in the current quarter. So we do see mobile as a 2014 opportunity.

Steve Rubis - Stifel, Nicolaus & Co., Inc., Research Division

Great. That's good news. And then in terms of your Private Portal business, I know, David, you spoke that you expect significant growth driven by the Blue Cross/Blue Shield contract. Can you give us a sense of magnitude on growth? Is this 20%, 50% or more or less? And do you foresee additional contracts -- or opportunities for additional contracts in the next year?

David J. Schlanger

Well, I'll start with the last part of your question. We do foresee the opportunity for additional contracts across their customer portfolio of health plan employer and now government customers. And it's still too early and we're not prepared to discuss the rate of growth for next year in the Private Portal.

Steve Rubis - Stifel, Nicolaus & Co., Inc., Research Division

Got it. Then my last question and I'll hop back in the queue. A couple of quarters ago you talked about possible deal or people interested in working with you. And I'm just wondering if that's still out there or if kind of the Avado acquisition and some of the advertising you're seeing for managed care organizations kind of answers that opportunity.

David J. Schlanger

Yes, I mean, we're always actively evaluating -- we're currently actively evaluating several potential opportunities for various types of transactions, including strategic partnerships and acquisitions. And we expect that as we move forward in our efforts to diversify our revenue steams and take advantage of some of the unique market opportunities we see out there, that strategic transactions both partnerships and acquisitions will play a role.

Operator

Our next question comes from Peter Stabler with Wells Fargo.

Unknown Analyst

This is Steve Cho [ph] filling in for Peter. I just wanted to see if I could get some additional color around the reception on the native ad campaigns and maybe some thoughts on other ad formats in the mobile monetization plan going forward, maybe like interstitial and video ads, just wondering if those are the areas of strategic importance going forward.

David J. Schlanger

Yes, I mean we're -- across our platform, not just on mobile, one of the things we want to make sure as we look to optimize and maximize our monetization opportunities from our core advertising and sponsorship business is to make sure we have all the ad formats and ad technologies that advertisers are looking for. So whether they're interstitial, the rich media units, we're going to make sure that we're going to offer those to advertisers. And as you know, in the native world, there are many brands and advertisers that have invested in content, but they don't have a good platform to get people to engage with that content or to find that content. And because of our scale and because of the trust people have with us we believe that WebMD and Medscape are excellent platforms for those organizations with content marketing strategies to take advantage of. So again, starting with the Medscape side of things, we're seeing early success of our native ad initiatives and we're in the process of rolling out native capabilities more broadly across our product portfolio.

Unknown Analyst

Great to hear. And just one quick follow-up, programmatic seems to be a hot topic these days. I was just wondering if you guys are seeing any demands or thoughts from advertisers about putting more of your inventory into those channels?

David J. Schlanger

Yes. We have a very unique audience that, as I've mentioned before, that is not available elsewhere. And substantially all of our sales are from directly-sold programs. And so except for very limited cases on a very small scale, with respect to some rendered inventory, we are not taking advantage of any of the programmatic technologies in the marketplace and don't expect to going forward.

Operator

[Operator Instructions] Our next question comes from Sandy Draper with Raymond James.

Alexander Y. Draper - Raymond James & Associates, Inc., Research Division

I guess, first off, if you could maybe talk a little bit your comments about in that customers who have left sort of coming back and who have been with other digital format, without necessarily naming a specific competitor, are there -- was it broader or sort of people just started spending on broader advertising campaigns or were they going to other health care specific sites? I mean, any sense on sort of where they went and I'm just trying to understand exactly what's driving them to come back? Because obviously, it's great news. I'm just trying to understand the trend there.

Peter Anevski

So of the customers that have shared with us those experiences, some of those did a combination of either going to other competitors and/or buying just general audience and to -- however they measured whatever results they saw, they basically came back and looked for value from the programs that we deliver.

Alexander Y. Draper - Raymond James & Associates, Inc., Research Division

Okay, great. That's really helpful. And then maybe one more follow-up on the FEP. I know you don't want to get and can't get in to too much specific there. But is there any part of that contract that is -- is there sort of a guaranteed amount of employers or employees that are going to be taking up that are going to be paid for? Or is it purely, you roll out the program and in theory, if no employers took or employees took it on, you wouldn't get paid? Just trying to understand if there's a physical guarantee for certain amount of work that could expand? Or is it all based on the uptake of that customer?

David J. Schlanger

It's a fairly complicated contract and it includes both elements that are volume-based and elements that are population-based. But the program does cover the 5.5 million federal employees that are accessing their benefits through the Blue Cross association.

Peter Anevski

Yes. And we're actively working with FEP in the implementation of that program and fully expect it to be a success.

Operator

We have a follow-up question from Steve Rubis with Stifel.

Steve Rubis - Stifel, Nicolaus & Co., Inc., Research Division

In terms of mobile, you had a recent industry conference, it seemed to that people are interested in advertising there and that you have no problem attracting advertisers. But in terms of monetization, what are the early trends there? And where do you see it falling out compared to your PC rates and et cetera?

David J. Schlanger

Well, it's really not an apples-to-apples comparison. Mobile is a different form factor, the screen size makes it different. But all I would say is that what we are seeing with respect to our mobile audience is -- are strong CPMs comparable to what we -- what we're able to capture on the desktop for similar types of advertising. But again, the mobile opportunity, for us, we view is incremental because we have substantial inventory in the desktop for our current revenue expectations and customers are coming to us with incremental mobile budgets beyond what their spending on the desktop.

Steve Rubis - Stifel, Nicolaus & Co., Inc., Research Division

Got it. That's interesting. And then finally, can you guys give us some color or some thoughts behind the timing and the impetus to repurchase the stake from Carl Icahn and how it kind of relates to the tender offer?

Martin J. Wygod

There's really no correlation between the tender offer and the purchasing of the Icahn position. They've tended part of their shares on the tender offer and this was the remaining major overhang that we threw out there. And because of the positive prospects in the company we felt comfortable in acquiring their shares. I think that pretty much is the full story on it.

Operator

I will hand it back to David Schlanger for comments as we show no further questions.

David J. Schlanger

Thanks, operator. So I'd like to thank all of you that dialed in today for joining us on the call. Just to reiterate what we said earlier, we're very pleased with the results we reported for the third quarter and with our outlook for the remainder of the year. And although it's still premature, but based on the sales momentum that we're currently experiencing, this is a strong indicator that we will continue to have positive momentum going into 2014.

And operator, thanks. And I think we can terminate the call at this point.

Operator

Thank you. As a reminder, if necessary, there's a replay available of this call which can be accessed toll-free at (855) 859-2056, or if you're calling from outside the U.S., at (404) 537-3406. The passcode is 80276289. There's also webcast replay available on www.wbmd.com.

Thank you for joining us today. You may all disconnect.

Copyright policy: All transcripts on this site are the copyright of Seeking Alpha. However, we view them as an important resource for bloggers and journalists, and are excited to contribute to the democratization of financial information on the Internet. (Until now investors have had to pay thousands of dollars in subscription fees for transcripts.) So our reproduction policy is as follows: You may quote up to 400 words of any transcript on the condition that you attribute the transcript to Seeking Alpha and either link to the original transcript or to www.SeekingAlpha.com. All other use is prohibited.

THE INFORMATION CONTAINED HERE IS A TEXTUAL REPRESENTATION OF THE APPLICABLE COMPANY'S CONFERENCE CALL, CONFERENCE PRESENTATION OR OTHER AUDIO PRESENTATION, AND WHILE EFFORTS ARE MADE TO PROVIDE AN ACCURATE TRANSCRIPTION, THERE MAY BE MATERIAL ERRORS, OMISSIONS, OR INACCURACIES IN THE REPORTING OF THE SUBSTANCE OF THE AUDIO PRESENTATIONS. IN NO WAY DOES SEEKING ALPHA ASSUME ANY RESPONSIBILITY FOR ANY INVESTMENT OR OTHER DECISIONS MADE BASED UPON THE INFORMATION PROVIDED ON THIS WEB SITE OR IN ANY TRANSCRIPT. USERS ARE ADVISED TO REVIEW THE APPLICABLE COMPANY'S AUDIO PRESENTATION ITSELF AND THE APPLICABLE COMPANY'S SEC FILINGS BEFORE MAKING ANY INVESTMENT OR OTHER DECISIONS.

If you have any additional questions about our online transcripts, please contact us at: transcripts@seekingalpha.com. Thank you!